Table 2.
Passive immunization candidates currently in clinical trials.
| Target (αsyn) | Name | Companies | Antibody/Clone | Binding Site (aa) | Clinical Groups | Current Clinical Phase | Clinical Trial ID |
|---|---|---|---|---|---|---|---|
| Aggre. | PRX002/(Prasinezumab)–PASADENA study | Hoffman-La Roche; Prothena Biosciences Limited. |
Humanized IgG1 mab version of murine 9E4 | Preferable aggregated αsyn within the C-terminal at aa 118–126 (VDPDNEAYE) |
PD patients (H&Y < 2) | Phase II; active; recruitment completed. |
NCT03100149 |
| Aggre. (Oligo/proto-fibrils) | ABBV-0805 | AbbVie; BioArctic Neuroscience AB | Humanized mAB47 mab | Preferable aggregated αsyn within the C-terminal at aa 121–127 (DNEAYEM) | PD patients (<5 years from diagnosis and H&Y < 3) | Phase I; recruiting. | NCT04127695 |
| Aggre. | MEDI1341 | Astra Zeneca; Takeda Pharmaceuticals |
Humanized IgG1 mab | Preferable aggregated αsyn within the C-terminal (within the aa 103–129 region) | Healthy individuals (MEDI1341 vs. placebo) | Phase I; recruitment completed. | NCT03272165 |
| Aggre. | BIIB054 (Cinpanemab)–SPARK study | Biogen; Neuroimmune | Healthy human memory B cells derived mab | Preferable aggregated αsyn, oxidized at N-terminal aa: 4–10 (FMKGLSK) | PD patients (<3 years from diagnosis and H&Y < 2.5) | Phase II; Terminated |
NCT03318523 |
| Aggre. | Lu AF82422–AMULET study | H. Lundbeck A/S; Genmab A/S |
Humanized IgG1 mab | Preferable aggregated αsyn within the C-terminal at aa 112–117 (ILEDMP) | MSA-P and MSA-C patients (<5 years from diagnosis, UMSARS ≤ 16, MoCA ≥ 22) | Phase II; recruiting | NCT05104476 |
Abbreviations: αsyn: alpha-synuclein, mab: monoclonal antibodies, aggre: aggregates/aggregated, aa: amino acids, oligo: oligomers/oligomeric.